Epilepsy, Unspecified, Intractable Clinical Trial
Official title:
Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody
The purpose of the study is to investigate effect of immunotherapy in intractable cryptogenic epilepsy patients with autoimmune antibody.
Cryptogenic epilepsy is an epilepsy of presumed symptomatic nature but the cause has not
been identified. It account for at least 40% of adult-onset epilepsy. Autoimmune
encephalitis including classic paraneoplastic syndrome and autoimmune synaptic encephalitis
is a new category of immune-mediated disorders which often has favorable outcome. Recent
studies reported that immunotherapy improves seizure outcome in medically intractable
epilepsy patients with clinical and serological evidence of an autoimmune basis. Neural
autoantibodies were detected in 22% of epilepsy due to unknown cause in a study, mostly from
the antiepileptic drug(AED)-resistant epilepsy group. Of the patients who received
immunotherapy, 75% archived >50% reduction in seizure frequency.
Many patients with cryptogenic epilepsy are refractory to AED and significant percent of
cryptogenic epilepsy harbor neural autoantibody. In those cases, immunotherapy is suggestive
based on favorable outcome of immunotherapy in autoimmune encephalitis and autoimmune
epilepsy. Investigators aim to investigate the response to immunotherapy in intractable
cryptogenic epilepsy patients with neural autoantibodies.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment